French Senate proposes lifecycle pricing model for innovative medicines

France’s Senate has set out 27 recommendations to reshape the route from clinical development to routine reimbursement for innovative medicines, with linked proposals on health technology assessment, pricing and early access. The report, L’innovation thérapeutique (Therapeutic innovation), was prepared by the Social Security Evaluation and Control Mission (Mission d’évaluation et de contrôle de la sécurité sociale, Mecss) for the Senate Social Affairs Committee and published on 8 July.

The most distinctive pricing proposal is a multi-year ‘price trajectory’ for innovative medicines. The Senate proposes an attractive launch price, guaranteed for a period linked to the level of added therapeutic benefit, followed by steeper reductions later in the product lifecycle. Subsequent price changes could reflect real-world effectiveness, sales volumes and the arrival of competing treatments.

The proposal is close to the direction already being explored by the Economic Committee for Health Products (Comité économique des produits de santé, CEPS). Its president, Virginie Beaumeunier, told the National Assembly in March that CEPS wanted a predictable multi-year price path, with scheduled reviews every two or three years, as part of negotiations on the next CEPS-industry framework agreement.

The recommendations would also make assessment more adaptable where evidence remains immature. The French National Authority for Health (Haute Autorité de santé, HAS) could issue a temporary assessment while further evidence is generated, or defer its decision where existing data do not support a sufficiently robust conclusion. The Senate also wants health-economic assessment to give greater weight to avoided treatment costs and wider effects on healthcare organisation. A separate recommendation would recognise clinical-research investment in France within pricing, potentially making part of the price conditional on enrolment of French patients in clinical trials.

Early access receives particular attention. Medicines can remain funded through early access after marketing authorisation and after the ordinary HAS appraisal while CEPS negotiates the price required for routine reimbursement. The Senate proposes limiting this period to one year after the ordinary Transparency Committee assessment, with a further six months possible at the company’s request and with CEPS agreement.

The proposed limit responds to evidence that early access can reduce the commercial incentive to conclude price negotiations promptly. A medicine without exceptional access generates little or no revenue while negotiations continue, whereas an early-access medicine remains reimbursed during this period at a provisional amount set by the company, subject to subsequent financial adjustment. The Senate reports a median CEPS negotiation period of 175 days for products that had received early access, compared with 70 days for those that had not. More than 40% of HAS early-access applications are now renewals, including some products that have held marketing authorisation and completed ordinary assessment for several years. The Senate therefore wants to preserve early access for its intended purpose while preventing prolonged negotiations from delaying transition to routine reimbursement.

The report also proposes making the newer direct-access pathway permanent, widening eligibility and adjusting negotiation deadlines. Direct access applies after HAS has assessed a medicine as innovative and provides temporary reimbursement while routine listing and price negotiation are completed.

US Most Favoured Nation pricing forms part of the report’s wider rationale. Citing a pharmaceutical industry association (Les Entreprises du Médicament, LEEM) survey, the Senate reports that 64% of respondents expect the US policy to reduce new-product launches in France strongly or moderately over the next three years. CEPS has separately confirmed that manufacturers are already raising MFN policy during price negotiations.

The Senate consequently supports continued confidentiality of product-level net prices, alongside confidential parliamentary access to selected CEPS pricing information, and calls for stronger European negotiating cooperation. Taken together, its recommendations point towards a more dynamic French access model: greater reward for genuine innovation at launch, planned price erosion later, more flexible handling of immature evidence and firmer deadlines for moving medicines from exceptional access into routine reimbursement.

Source 1: French Senate
Link: L’innovation thérapeutique (Therapeutic innovation)
Date: 8 July 2026

Source 2: French National Assembly Social Affairs Committee
Link: Compte rendu n° 57 (Report no. 57)
Date: 25 March 2026